News
To keep up-to-date with the latest in regulatory science, follow CIRS on LinkedIn. You can also sign up to the CIRS mailing list.
For CIRS publications including R&D Briefings, journal articles and reports, please visit the Publications area.
Regulatory processes for rare disease drugs in the US and EU: National Academies study supported by CIRS
A new report from the NASEM Health and Medicine Division offers recommendations for enhancing rare disease drug development. CIRS is delighted to have been able to collaborate with NASEM [...]
Incentives for rare disease products
The Centre for Innovation in Regulatory Science (CIRS) held a multi-stakeholder workshop that examined current regulatory and reimbursement frameworks for rare disease products (orphan drugs), reviewing how these can [...]
Latest CIRS research posters
So far 2024 has been a busy year conference wise for CIRS! CIRS staff have presented work and/or moderated sessions at several conferences including DIA Europe, RAPS Euro Convergence, [...]
Establishing a baseline for monitoring the impact of the EU HTA Regulation
Timely availability of new medicines to patients is crucial for public health. This process involves several phases: the time taken for regulatory approval, the time to health technology assessment [...]
New CIRS Research Agenda
We're pleased to announce that CIRS has published a new Research Agenda, which can be downloaded here. This brochure outlines our research priorities for 2024-2026 as well as plans for [...]
Webinar on approaches to implementing regulatory reliance
We recently presented key findings from our latest R&D Briefing in a webinar on 'Approaches to Implementing Regulatory Reliance: Considerations for Agencies'. The webinar was attended by over 200 people [...]
Welcome our new HTA Research Analyst
We’re thrilled to welcome Penelope Cervelo as the new CIRS Research Analyst! Penelope will work closely with Dr Tina Wang and Dr Belen Sola on HTA projects and activities, [...]
How effective and efficient is the ZaZiBoNa collaborative initiative?
As part of the Optimising Efficiencies in Regulatory Agencies (OpERA) programme, CIRS has been working closely with the regulatory agencies who are active in ZaZiBoNa, the Southern African Development [...]
Impact of orphan designation on HTA recommendation time
In recognition of Rare Disease Day 2022, we thought we’d share some insights on the impact of regulatory orphan drug designation on the time to HTA recommendation. Regulatory orphan designation [...]
Where to meet CIRS – upcoming conferences
We're pleased to be involved in the following conferences coming up in the first half of 2022. Please do come and say hello! 14-16th [...]